Is Adeshwar Meditex overvalued or undervalued?

As of 7 November 2025, Adeshwar Meditex has moved from an expensive to a fair valuation grade. The company's current valuation indicates it is fairly valued. Key ratios include a PE ratio of 12.77, an EV to EBITDA of 8.25, and a Price to Book Value of 0.71, which suggest a reasonable pricing relative to its earnings and assets.
In comparison to its peers, Adeshwar Meditex's PE ratio is significantly lower than that of Poly Medicure, which stands at 53.67, and Blue Jet Health at 29.26, both categorized as very expensive. The company's EV to EBITDA ratio of 8.25 also positions it more favorably compared to peers like Vimta Labs, which has an EV to EBITDA of 25.64. Notably, while Adeshwar Meditex has underperformed the Sensex over the longer term, it has shown a positive return of 3.95% over the past week, contrasting with the Sensex's decline.